Frontlight ResearchEarly access
CompletedNo phase
A Clinical Study to Determine the Safety and Efficacy of An Oral Probiotic Supplementation in the Management of Irritable Bowel Syndrome With Protein Digestion.
Key facts
- Who runs it
- NovoBliss Research Pvt Ltd
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 18 people enrolled
- Started
- 30 Nov 2024
- Ended
- 30 Nov 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MetBroma
- Record updated
- 31 July 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- The subject is an adult male or female aged between 18 to 60 years old
- Clinically diagnosed with irritable bowel syndrome (IBS) based on Rome IV criteria: Abdominal pain at least 4 days per month - over at least 2 months - associated with one or more of the following:; Related to defecation ii. A change in frequency of stool iii. A change in form (appearance) of stool iv. After appropriate evaluation, the symptoms cannot be fully explained by another medical condition
- The subject is having refrigerator at their home for storage of test treatment
- The subject is willing to provide written informed consent, comply with the study procedures, and be present for all the visits
- The subject is willing to abstain from using any other treatments for irritable bowel syndrome during the study period, unless for a medical urgency
- The subject is in a stable medical condition, not requiring immediate intervention or hospitalization
- If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation; Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device/injection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence)
- Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration
Who cannot take part
- The subject has used medications that could influence the study outcomes, such as antibiotics, immunosuppressive drugs, and probiotics or prebiotics supplements within the last 4 weeks
- The subject has participated in other clinical studies or received any investigational agent in the previous 30 days
- The subject has a history of diagnosis of either hypertension, diabetes, or liver disease
- The subject has any other significant medical condition that could interfere with the study or pose a risk to the participant
- The subject has a history of alcohol abuse
- The subject has other significant gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis, celiac disease)
- The subject has any condition that, in the investigator's judgment, would compromise the subject's safety or study integrity
- The subject has abnormal baseline Haemoglobin (Hb), Complete Blood Count (CBC), Urine Routine/Microscopy (R/M), or Stool Routine/Microscopy (R/M) results that suggest a different pathology than irritable bowel syndrome
- The subject works in frequent night shifts (working night shifts at least 3 times per week), and refuses to change the lifestyle
- The subject is either pregnant, lactating, or plans on conceiving during the course of the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, two-arm, prospective, interventional, in-use safety and efficacy study of an oral probiotic supplementation in adult subjects having irritable bowel syndrome.
The 2 groups in the trial
- MetBromaTreatment being tested
Active Ingredients: Bromelain Mode of Usage: Take one slow-release capsule twice a day, after meal with water Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
- PlaceboPlacebo, for comparison
Mode of Usage: Take one slow-release capsule twice a day, after meal with water Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
Treatment: MetBroma
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Preliminary Investigation of the Safety and Effectiveness of Oral Probiotics Supplementation for Management of Irritable Bowel Syndrome: A Randomized, Open Label, Placebo-Arm, Comparative, Interventional, Proof-of-Science Study
- Record updated
- 31 July 2026